Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1

被引:39
作者
Devico, AL
Fouts, TR
Shata, MT
Kamin-Lewis, R
Lewis, GK
Hone, DM
机构
[1] Univ Maryland, Inst Biotechnol, Inst Human Virol, Div Vaccine Res, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA
关键词
prime-boost strategy; neutralizing antibodies; HIV-1;
D O I
10.1016/S0264-410X(02)00080-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Given the increasing incidence of HIV-1 infection world-wide, an affordable, effective vaccine is probably the only way that this virus will be contained. Accordingly. our group is developing an oral prime-boost strategy with the primary goal of eliciting broadly neutralizing antibodies against HIV-1 to provide sterilizing immunity for this virus. Our secondary goal is to elicit broadly cross-reactive anti-viral CD8(+) T cells by this strategy to blunt any breakthrough infections that occur after vaccination of individuals who fail to develop sterilizing immunity. This article describes our progress in the use of the live attenuated intracellular bacteria, Salmonella and Shigella. as oral delivery vehicles for DNA vaccines and the development of conformationally constrained HIV-1 Env immunogens that elicit broadly neutralizing antibodies. (C) 2002 Published by Elsevier Science Ltd.
引用
收藏
页码:1968 / 1974
页数:7
相关论文
共 83 条
  • [1] Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
    Amara, RR
    Villinger, F
    Altman, JD
    Lydy, SL
    O'Neil, SP
    Staprans, SI
    Montefiori, DC
    Xu, Y
    Herndon, JG
    Wyatt, LS
    Candido, MA
    Kozyr, NL
    Earl, PL
    Smith, JM
    Ma, HL
    Grimm, BD
    Hulsey, ML
    Miller, J
    McClure, HM
    McNicholl, JM
    Moss, B
    Robinson, HL
    [J]. SCIENCE, 2001, 292 (5514) : 69 - 74
  • [2] ΔguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin
    Anderson, RJ
    Pasetti, MF
    Sztein, MB
    Levine, MM
    Noriega, FR
    [J]. VACCINE, 2000, 18 (21) : 2193 - 2202
  • [3] André S, 1998, J VIROL, V72, P1497
  • [4] Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
    Baba, TW
    Liska, V
    Hofmann-Lehmann, R
    Vlasak, J
    Xu, WD
    Ayehunie, S
    Cavacini, LA
    Posner, MR
    Katinger, H
    Stiegler, G
    Bernacky, BJ
    Rizvi, TA
    Schmidt, R
    Hill, LR
    Keeling, ME
    Lu, YC
    Wright, JE
    Chou, TC
    Ruprecht, RM
    [J]. NATURE MEDICINE, 2000, 6 (02) : 200 - 206
  • [5] Transgene as vaccine for chlamydia
    Brunham, RC
    Zhang, DJ
    [J]. AMERICAN HEART JOURNAL, 1999, 138 (05) : S519 - S522
  • [6] Introduction of protein or DNA delivered via recombinant Salmonella typhimurium into the major histocompatibility complex class I presentation pathway of macrophages
    Catic, A
    Dietrich, G
    Gentschev, I
    Goebel, W
    Kaufmann, SHE
    Hess, J
    [J]. MICROBES AND INFECTION, 1999, 1 (02) : 113 - 121
  • [7] ANTIBODY RAISED AGAINST SOLUBLE CD4-RGP120 COMPLEX RECOGNIZES THE CD4 MOIETY AND BLOCKS MEMBRANE-FUSION WITHOUT INHIBITING CD4-GP120 BINDING
    CELADA, F
    CAMBIAGGI, C
    MACCARI, J
    BURASTERO, S
    GREGORY, T
    PATZER, E
    PORTER, J
    MCDANAL, C
    MATTHEWS, T
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (04) : 1143 - 1150
  • [8] Courvalin P, 1995, CR ACAD SCI III-VIE, V318, P1207
  • [9] Oral somatic transgene vaccination using attenuated S-typhimurium
    Darji, A
    Guzman, CA
    Gerstel, B
    Wachholz, P
    Timmis, KN
    Wehland, J
    Chakraborty, T
    Weiss, S
    [J]. CELL, 1997, 91 (06) : 765 - 775
  • [10] Darji A, 2000, FEMS IMMUNOL MED MIC, V27, P341